Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
-
BUSINESS Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
-
REGULATORY Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
-
BUSINESS Metal Found in Voltaren Product Again: Novartis
April 17, 2014
-
ORGANIZATION Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
-
BUSINESS FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
-
BUSINESS Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
-
ACADEMIA Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
-
BUSINESS 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
-
BUSINESS Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
-
BUSINESS Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
-
BUSINESS India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
-
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
-
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
-
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
-
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…